Zacks: Analysts Expect Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.07 Per Share

Equities research analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to post earnings of ($0.07) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 70.8%. The firm is expected to announce its next earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.43) to ($0.40). For the next financial year, analysts anticipate that the company will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.83) to ($0.31). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02.

EVOK has been the subject of several recent research reports. HC Wainwright set a $9.00 target price on shares of Evoke Pharma and gave the stock a “buy” rating in a research report on Friday, August 17th. ValuEngine downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Friday, August 17th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.35.

In other Evoke Pharma news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of the firm’s stock in a transaction dated Monday, August 20th. The stock was bought at an average cost of $2.35 per share, with a total value of $1,175,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 11.94% of the company’s stock.

Shares of NASDAQ EVOK opened at $2.65 on Friday. Evoke Pharma has a 1-year low of $1.85 and a 1-year high of $4.09. The stock has a market cap of $50.36 million, a PE ratio of -3.19 and a beta of 1.46.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Read More: Diversification

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply